AI Article Synopsis
- The study reviewed the experiences of 32 patients diagnosed with metachronous second primary lung cancers from January 1983 to April 2004.
- Surgical options included lobectomy, pneumonectomy, and limited resections, with a postoperative morbidity rate of 12% and mortality rate of 3%.
- The survival rates post-surgery indicated 66% at 1 year, decreasing to 19% at 5 years, highlighting the importance of close monitoring after initial lung cancer treatment to improve early diagnosis of subsequent cancers.
Article Abstract
Objective: To review the experience of the diagnosis, surgical treatment and prognosis of metachronous second primary lung cancers.
Methods: Between January 1983 and April 2004, 32 patients with metachronous second primary lung cancers were operated in our department. Clinical data of all these patients were reviewed retrospectively.
Results: The initial procedures for their first primary lung cancers were lobectomy or pneumonectomy. Lobectomy or completion pneumonectomy for the second primary lung cancers were performed in 17 cases, limited pulmonary resection was done in 14 cases and exploration was in 1 case. The postoperative morbidity and mortality were 12% (4/32) and 3% (1/32), respectively. The 1-, 3-, and 5-year survival rate after second operation were 66% (19/29), 32% (9/28) and 19% (4/21), respectively.
Conclusions: The incidence of metachronous second primary lung cancers has been increasing gradually during recent years. The closely follow-up for patients undergoing resection for their first primary lung cancers is most important factor for improvement of the diagnosis of metachronous second primary lung cancers. Limited resection and incomplete lymph node dissection might be the factors contributing to the poor prognosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Preoperative immunochemotherapy versus chemotherapy as first-line treatment for patients with stage I-IIIB small-cell lung cancer.
BMC Cancer
January 2025
Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Background: To date, there remains a paucity of comparative investigations pertaining to preoperative immunochemotherapy and conventional chemotherapy in the context of limited-stage small-cell lung cancer (LS-SCLC) patients. This study conducted a comprehensive comparative assessment concerning the safety and efficacy profiles of preoperative immunochemotherapy and chemotherapy in individuals diagnosed with stage I-IIIB SCLC.
Methods: This investigation collected 53 consecutive patients diagnosed with LS-SCLC spanning stage I to IIIB who underwent preoperative immunochemotherapy or conventional chemotherapy at our hospital from January 2019 to July 2021.
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma.
Clin Lung Cancer
December 2024
Georgetown University, Washington, DC. Electronic address:
Background: Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare thoracic tumors of the anterior mediastinum. For those with advanced disease, platinum-based chemotherapy is used as first-line treatment. However, there is no standard regimen established for TET at progression after initial therapy, and treatment options for advanced/recurrent TETs are limited.
View Article and Find Full Text PDFScreening Criteria Evaluation for Expansion in Pulmonary Neoplasias (SCREEN) II.
Can J Surg
January 2025
From the Faculty of Medicine, Dalhousie University, Halifax, N.S. (Huo); the Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece (Kontouli); the Department of Diagnostic Radiology, Dalhousie University, Halifax, N.S. (Manos); the Department of Pathology, Dalhousie University, Halifax, N.S. (Xu, Fris); the Department of Urology, Dalhousie University, Halifax, N.S. (Chun); the Division of Thoracic Surgery, Department of Surgery, Dalhousie University, Halifax, N.S. (Wallace, French)
Background: There is a need to expand eligibility criteria for lung cancer screening beyond age and smoking history. In this study, we sought to assess whether light-or-never-smokers and heavy smokers differ in molecular and immunologic markers based on conventional lung cancer screening criteria.
Methods: We conducted a retrospective review of lung cancer cases from 2005 to 2018 at a tertiary Canadian institution.
Association between chronic respiratory diseases and frailty in Chinese elderly: a population-based longitudinal study.
BMJ Open Respir Res
January 2025
Peking University, Beijing, China
Background: Chronic respiratory diseases (CRDs) have been shown to be associated with frailty, but these findings have not yet reached a consensus. The aim of this study was to investigate the association between CRDs and frailty in the elderly using a nationally representative data from China.
Methods: Data from the China Health and Retirement Longitudinal Study (CHARLS) were analysed, including 3309 frailty-free participants followed for three waves from 2011.
When "loss-of-function" means proteostasis burden: Thinking again about coding DNA variants.
Am J Hum Genet
January 2025
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Each human genome has approximately 5 million DNA variants. Even for complete loss-of-function variants causing inherited, monogenic diseases, current understanding based on gene-specific molecular function does not adequately predict variability observed between people with identical mutations or fluctuating disease trajectories. We present a parallel paradigm for loss-of-function variants based on broader consequences to the cell when aberrant polypeptide chains of amino acids are translated from mutant RNA to generate mutated proteins.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!